openPR Logo
Press release

Multiple Sclerosis Therapeutics Market Size, Status, Top Emerging Trends, Growth and Business Opportunities 2025

07-07-2021 08:12 PM CET | Health & Medicine

Press release from: Fairfield Market Research

Multiple sclerosis has long been among the leading cause of neurological disabilities worldwide and the direct and indirect costs associated with it remain a major challenge in the multiple sclerosis therapeutics market. Nonetheless, an uptick in the patients suffering from relapsing remitting multiple sclerosis RRMS) and secondary progressive multiple sclerosis (SPMS) should spur adoption of therapeutics equipment.

Get PDF Sample Copy of this Report (Including Full TOC, List of Tables & Figures) :

https://www.fairfieldmarketresearch.com/report/multiple-sclerosis-therapeutics-market/

Lack of Trust in Generic Molecules Poses Problems in Multiple Sclerosis Therapeutics Market

The critical need for rapid-action drugs in the progressive multiple sclerosis sector is the key driver in the multiple sclerosis therapeutics market. For e.g. – Biogen Idec launched Plegridy – a long-acting variant of its interferon Avonex. Healthcare marketers must improve the safety, tolerability, and dosage of their offerings in the multiple sclerosis therapeutics market. A lack of trust due to generic molecules and biosimilars, coupled with prohibitive costs are detrimental to growth in the multiple sclerosis therapeutics market. The Blue Cross/ Blue Shield estimates that multiple sclerosis drugs in the U.S are more than twice the price of other drugs.

Hormonal Differences Make Women Significantly More Vulnerable Than Men to RRMS

The vast majority of multiple sclerosis cases are relapsing remitting multiple sclerosis. RRMS involves episodes of increasing symptoms that are followed by periods of remission. In 2013, a study conducted by the International Progressive Alliance stated that women are three times more vulnerable than men to RRMS. RRMS typically follows a clinically isolated syndrome (CIS) – with symptoms that are longer than a day. In addition, approx. half of patients progress to SPMS within a decade of being diagnosed with RRMS.

In Order to place the Purchase Query Click Here: sales@fairfieldmarketresearch.com

Convenience of Oral Therapies Explain Their Popularity in the Multiple Sclerosis Therapeutics Market

Disease modifying therapies usually target RRMS and SPMS in the multiple sclerosis therapeutics market. In terms of treatment options, consumers have expressed a clear preference for oral therapies in lieu of injectable ones. Gilenya began the oral therapy boom in 2011 and consolidated its competitive position two years later with Tecfidera – the current leader in the multiple sclerosis therapeutics market. However, oral therapies have been unable to dislodge self-injectable medication from their dominant position in the multiple sclerosis therapeutics market.

A trend of note in the multiple sclerosis therapeutics market has been the growth of infusion therapy. In 2013, Lemtrada – a drug to treat multiple sclerosis was granted regulatory approval by the European Medicines Agency (EMA). Presently, Ocrevus is the only drug approved by the FDA for treating PPMS. Newer compounds such as Zeposia and Kesimpta are likely to intensify competition in the multiple sclerosis therapeutics market. Drugs in phase three clinical trials include Fenebrutinib and Tolebrutinib.

Cash-rich Companies Leave Rivals in Dust in Multiple Sclerosis Therapeutics Market

The three most prescribed brand-name drugs in the multiple sclerosis therapeutics market are Biogen’s Tecfidera, Novartis’ Gilenya, and Roche Holding’s Ocrevus in that order respectively. Experts predict that Ocrevus has extremely promising growth prospects and should gain market share at the expense of its closest rivals. Other major brand-name drugs in the multiple sclerosis therapeutics market comprise Tysabri and Avonex (Biogen Inc.), Copaxone (Teva Pharmaceutical Industries Ltd.), Rebif (Merck KGaA), Aubagio and Lemtrada (Sanofi S.A.), and Betaferon (Bayer AG).

Browse Our Latest Reports: https://www.fairfieldmarketresearch.com/shop/

Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA +1 (844) 3829746 (Toll-free)
Email: mail@fairfieldmarketresearch.com
Follow us on LinkedIn: https://bit.ly/3voYIm9

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Multiple Sclerosis Therapeutics Market Size, Status, Top Emerging Trends, Growth and Business Opportunities 2025 here

News-ID: 2323640 • Views:

More Releases from Fairfield Market Research

Foot Care Products Market Forecast: US$ 19.33 Bn by 2032 with a CAGR of 4.6%
Foot Care Products Market Forecast: US$ 19.33 Bn by 2032 with a CAGR of 4.6%
The global foot care products market is on track to witness steady growth, projected to reach US$ 19.33 Bn by 2032 from US$ 14.15 Bn in 2025, expanding at a CAGR of 4.6% from 2025 to 2032. The rising prevalence of foot-related conditions, increasing wellness trends, and advancements in orthopedic solutions are key drivers of this growth. Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a
Gas Sensors Market to Hit US$ 3.48 Bn by 2032, Driven by 9.1% CAGR and Rising Environmental Concerns
Gas Sensors Market to Hit US$ 3.48 Bn by 2032, Driven by 9.1% CAGR and Rising En …
The global gas sensors market is set for significant growth, projected to reach US$ 3.48 Bn by 2032, up from an estimated US$ 1.89 Bn in 2025. This expansion is driven by rising environmental concerns, industrial safety regulations, and technological advancements. The market is anticipated to grow at a CAGR of 9.1% from 2025 to 2032. Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick
Graphene Market to Hit $3.12 Bn by 2032, Growing at 26.9% CAGR
Graphene Market to Hit $3.12 Bn by 2032, Growing at 26.9% CAGR
The global graphene market is set for a significant expansion, with projections indicating growth from US$ 589.4 Mn in 2025 to US$ 3,123.7 Mn by 2032, at a robust CAGR of 26.9%. The rising demand for graphene across various industries, including electronics, energy storage, automotive, and aerospace, is expected to drive this growth. Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.fairfieldmarketresearch.com/report/graphene-market/request-sample Market Insights • The
Vaccine Adjuvants Market Forecast: Robust Growth Driven by Technological Advancements and Rising Immunization Initiatives
Vaccine Adjuvants Market Forecast: Robust Growth Driven by Technological Advance …
The global vaccine adjuvants market is poised for substantial growth, projected to reach US$ 4.33 billion by 2032, up from an estimated US$ 1.69 billion in 2025. This represents a CAGR of 14.3% from 2025 to 2032. Increasing demand for innovative vaccine adjuvants due to the rising prevalence of infectious diseases and technological advancements in immunization are key growth drivers. Get a Sample PDF Brochure of the Report (Use Corporate Email

All 5 Releases


More Releases for RRMS

Secondary Progressive Multiple Sclerosis Drug Market Size, Share, Analysis, Indu …
The global secondary progressive multiple sclerosis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Secondary progressive MS (SPMS) is a form of MS that occurs after relapsing-remitting MS. The disease varies across individuals and does not occur in all the patients who priorly have RRMS. The major factor contributing to the growth of the market is the increasing prevalence of the disease across
COVID-19 Impact on Interferon Beta Drugs Market - Global Industry Analysis, Size …
Interferon Beta Drugs Market: Overview Interferon beta (IFNβ) therapy has been a first-line treatment or disease-modifying therapy for multiple sclerosis (MS). For the last 15 years, these drugs have been found useful in relapsing remitting multiple sclerosis (RRMS). A number of trials and post-marketing studies have harped on the use of interferon beta drugs in slowing progression of the disease and even reducing disease activity interferon-β-1b. A number of pharmacotherapies have
Multiple Sclerosis Drugs Market Valuable Growth Prospects and Upcoming Trends Ti …
Multiple Sclerosis Drugs Market: Introduction In terms of revenue, the multiple sclerosis drugs market is projected to expand at a CAGR of ~6% during the forecast period, due to numerous factors, about which TMR offers comprehensive insights and forecasts in the global multiple sclerosis drugs market report. Multiple sclerosis is a central nervous system disorder. It is a potentially disabling disease of the spinal cord and brain. In multiple sclerosis, the immune
Multiple Sclerosis Global Key Players - Biogen, Merck KGaA, Teva, Sanofi, and No …
Multiple Sclerosis Overview Multiple Sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection, and neurodegeneration within the central nervous system. It is the most common cause of non-traumatic neurological disability in young adults, afflicting at least 2.5 million people worldwide. In most patients, the disease is characterized initially by episodes of reversible neurological deficits, which is often followed by progressive neurological deterioration over time. The precise etiology of
Secondary Progressive MS – Majority MS patients progress to SPMS indicating hu …
Multiple Sclerosis is an autoimmune disorder that happens in the Central nervous system of the body. Multiple Sclerosis involves the brain, optic nerves and the spinal cord and leads to the destruction of the insulation layer, Myelin, which covers the nerve fibers in the CNS. SPMS is characterized by a continuous increase in disability and worsening of symptoms with or without the period of relapses and remissions. As per the latest
PharmaPoint: Multiple Sclerosis - Global Drug Forecast And Market Analysis To 20 …
Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch